Status:
ACTIVE_NOT_RECRUITING
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial). The goal of this clinical research study is...
Detailed Description
To perform a DCE-CT scan, a small amount of a special dye (called "CT contrast medium") is injected by vein into the body. Several CT images are then taken over a few minutes to learn how much dye spr...
Eligibility Criteria
Inclusion
- Patient must be enrolled or being considered for enrollment on protocol 2010-0085.
- Patients must have metastatic renal cell carcinoma (RCC).
- Age \>/= 18 years.
- Subjects must have adequate renal function as defined by serum creatinine \< 1.5x upper limit of normal.
Exclusion
- Radiotherapy: Subjects may not have received prior radiotherapy to the index lesion within 4 weeks
- Female subjects who are pregnant or lactating.
- Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment).
- Allergy to CT contrast media requiring the administration of steroid prophylaxis.
Key Trial Info
Start Date :
January 5 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2029
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01224288
Start Date
January 5 2011
End Date
April 30 2029
Last Update
November 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030